Syndax Pharmaceuticals reported a significant miss on both Q2 EPS and sales estimates, indicating weaker-than-expected financial performance. Despite a substantial year-over-year increase in sales, the failure to meet analyst expectations is likely to be viewed negatively by the market.
Syndax Pharmaceuticals reported Q2 losses of $(0.55) per share, missing the analyst consensus of $(0.49) by 12.24%. Concurrently, quarterly sales of $72.788 million fell short of the $79.323 million estimate by 8.24%. While the company did show a 91.76% increase in sales year-over-year, the failure to meet analyst expectations for both key metrics is a significant negative signal. This performance suggests that the company's growth, while present, is not as robust as anticipated by the market, which could lead to downward pressure on the stock in the short term. For traders, this indicates potential selling pressure on SNDX as investors re-evaluate their positions based on the underperformance relative to expectations.